Cytokinetics(CYTK) - 2024 Q4 - Annual Report

Financial Position - As of December 31, 2024, the company's cash and investments totaled $1,221.1 million, including U.S. Treasury securities and corporate debt[290]. - The total assets increased to$1.4 billion as of December 31, 2024, compared to $824.3 million in 2023[310]. - Cash and cash equivalents decreased to$94.9 million as of December 31, 2024, from $113.0 million in 2023[310]. - The total stockholders' deficit improved to$(135.4) million as of December 31, 2024, from $(386.3) million in 2023[310]. - The company has an accumulated deficit of approximately$2.7 billion since inception[323]. - The company believes existing cash and investments will be sufficient to fund cash requirements for at least the next 12 months[325]. Revenue and Expenses - Total revenues for the year ended December 31, 2024, were $18.5 million, a significant increase from$7.5 million in 2023[312]. - Research and development expenses for 2024 were $339.4 million, slightly up from$330.1 million in 2023[312]. - The net loss for the year ended December 31, 2024, was $589.5 million, compared to a net loss of$526.2 million in 2023[312]. - The company incurred net cash used in operations of $395.9 million for the year ended December 31, 2024, compared to$414.3 million in 2023[319]. - The company reported stock-based compensation expense of $97.8 million for 2024, compared to$72.1 million in 2023[319]. Liabilities and Debt - The company recognized a loss of approximately $19.6 million in 2024 due to changes in the estimated fair value of liabilities[292]. - As of December 31, 2024, the liabilities related to revenue participation right purchase agreements were$462.2 million, with a non-cash interest expense of $(48.8) million recognized for the year[303]. - The carrying value of liabilities related to RPI transactions measured at fair value was$137.0 million as of December 31, 2024[308]. - The company has entered into revenue participation right purchase agreements, which are accounted for as liabilities to be amortized over the life of the related royalty stream, reflecting ongoing financial obligations[348]. - The company anticipates future minimum payments of $227.5 million under the RP OM Loan Agreement based on the specified repayment scenarios[374]. Market Risks - The company is exposed to market risks primarily related to interest rate sensitivities[289]. - A hypothetical 1$6.1 million as of December 31, 2024[291]. - The fair value of certain liabilities will increase as market interest rates decrease, potentially affecting future earnings[292]. - The discount rates for the liabilities ranged from 10% to 18% as of December 31, 2024, compared to 14% to 18% as of June 30, 2024[292]. Stock and Equity - The company closed a public offering of 9,803,922 shares at $51.00 per share, generating gross proceeds of approximately$575.0 million[439]. - The company issued 5,016,170 shares for net proceeds of $164.2 million under the Amended ATM Facility in 2023[448]. - The total grant-date fair value of options to purchase common stock vested was$57.5 million in 2024[442]. - As of December 31, 2024, the balance of outstanding stock options was 10,419,523 with a weighted average exercise price of $31.84[442]. - Stock-based compensation expense for 2024 was$97.84 million, up from $72.07 million in 2023 and$47.85 million in 2022, with research and development accounting for $44.01 million in 2024[455]. Future Outlook - The company anticipates continued operating losses and net cash outflows in future periods[323]. - The earliest expected commercial sales and revenue recognition is in 2025, following the NDA filing for aficamten in September 2024[324]. - The company plans to fund operations through strategic collaborations, equity sales, grants, and debt financing until achieving profitable operations[324]. - The company expects to fulfill the technology transfer related to the Bayer License Agreement in the first half of 2025[416]. Taxation - The company did not record an income tax provision in 2024, 2023, and 2022 due to net taxable losses[468]. - As of December 31, 2024, federal net operating loss carryforwards were$1,195.2 million, with state NOL carryforwards of $428.2 million[472]. - The valuation allowance on net deferred tax assets increased by$140.4 million in 2024 and $128.6 million in 2023[471]. - The company expects no material impact from the Inflation Reduction Act of 2022 on its consolidated tax provision for the year ending December 31, 2024[477].